Recent years have seen dramatic progress in the production and understanding of pluripotent cells, which, researchers hope, will ultimately provide the option of creating replacement cells, tissues or organs in the laboratory. There are currently three potential access routes to such cell therapies, including embryonic stem cells, induced pluripotent cells, and transdifferentiated cells (Curr. Biol. (2011) , 21, R235-R237).
However, challenges remain both in the fundamental science and in its translation to the clinic. The UK's Medical Research Council (MRC), together with other research councils and the government's Technology Strategy Board (TSB), has now outlined a detailed strategy suggesting what UK agencies and researchers should do over the next five years in order to retain their leading role in this field and drive it towards clinical application.
The forward-looking report, titled "A strategy for UK regenerative medicine" (http://www.mrc.ac.uk/ Newspublications/News/MRC008536), builds on a previous government report taking stock of past and current developments in the field, an analysis of investment and funding streams, and the outcomes of a "key opinion leaders workshop" held last September.
What to do
The workshop, which involved active researchers, clinicians and representatives from industry and funding agencies, was a kind of brainstorming, as one participant recalls it, and produced a preliminary summary which provided the eight main themes that are the backbone of the new strategy paper.
There are five themes spanning the natural course of R&D from basic research through to commercialisation, and another three overarching ones dealing with general issues such as interdisciplinarity and international competition and collaboration.
At the research front, where the UK already has established a strong position built on earlier pioneering achievements, including IVF and the cloning of Dolly the sheep, the report names a number of "drivers", which "include a need to increase our understanding of cellular reprogramming, differentiation and ageing, disease and reparative mechanisms, stem cell niches, the extracellular environment, genetic instability, of how we harness the immune response, advanced bioprocessing, and undertake predictive modelling of innovation and value systems." Funding for this research will continue to be made available, the report promises:
Feature
"Support for such investigations will be provided through response mode funding, and continued strategic investment in centres of excellence and partnerships with industry."
A £25m cross-council UK Regenerative Medicine Platform (UKRMP) is now accepting grant applications. It will also work closely with the TSB's "Catapult Centre Cell Therapy" set up at the end of last year.
"We welcome the UK government's continued commitment to regenerative medicine and the balance it has struck between basic and translational research," says Paul Fairchild, a director of the Oxford Stem Cell Institute of the James Martin 21 st Century School. "While we still need to do more work to address fundamental issues, such as the mechanisms of cellular reprogramming and ways of pacifying the immune response to replacement tissues, the anticipated benefits UK research councils have drawn up a strategic plan for the development of regenerative medicine, covering all aspects from basic research through to commercialisation. Michael Gross reports. to human health demand a strong emphasis on translational aspects and on bringing therapies to the clinic."
A roadmap for regenerative medicine
Fairchild's group has recently succeeded in producing human dendritic cells from induced pluripotent stem cells (iPS cells) using protocols that would be compatible with clinical applications. The underlying idea is that dendritic cells derived from the same source as a transplanted tissue or cell population would induce the recipient's immune system to accept the transplant as 'self' (Gene Therapy (2011 ) doi: 10.1038 /gt.2011 .
Considering the various therapeutic options to which stem cell research may translate, the report states that "given uncertainties regarding the efficacy and safety of these different approaches, it will be important to maintain studies of all". The logical next step is product development, which will also benefit from funding from the UKRMP and from the TSB's Catapult Centre. As methods in tissue engineering advance, growing tubeshaped organs such as the urethra in the lab is becoming feasible, while solid organs such as heart and liver are still out of reach. Once developed, cell therapies and replacement organs need to be clinically evaluated. There are intrinsic challenges in the process when it applies to living materials, as opposed to molecular agents, as cell cultures are much more difficult to standardise and may mutate over time.
So far, first-in-man and early phase clinical trials of regenerative medicine therapies are scarce, warns Martin Birchall from the Ear Institute at University College London, especially those with reasonable follow-up on which to base phase III studies and commercialisation. Birchall carried out the first stem cell transplant of a windpipe in 2008, pioneering a technique that involves stripping a donor organ of its own cells and repopulating the remaining protein scaffold with stem cells from the recipient. He is now working on the application of similar methods to the repair of the voice box (larynx), with clinical trials expected to begin in 2013. "The recent brainstorming session involving the UK RM community determined key areas where science had not caught up with our translational aspirations. These are those highlighted in the present call," he says.
"Clinicians have identified a wide array of unmet patient needs, and academic clinicians are trying to put putative regenerative medicine solutions through early phase clinical trials. Developing the areas highlighted here will help," Birchall acknowledges. However, he warns, "there remains a huge pre-clinical trial application and clinical good manufacturing practice capacity gap in the UK which will need to be urgently bridged if the early phase trials that will be lifeblood of the UKRM Catapult are actually going to deliver. Both areas (limiting technologies, and capacity) need addressing urgently, but this present call is an important step towards the first of these."
In the last step of the strategy, the products have to be commercialised to secure industrial production and delivery to the clinic. Given the fundamental differences between cell therapies and conventional drug therapies, the report acknowledges that new business models may be required, and that funding may be necessary to get this development started.
How to do it
The remaining three strategic themes of the report are covering general aspects of how to do the work. Developments should focus on clearly defined medical targets, the report suggests. Therefore, "the sponsors will work, in a second phase of the UKRMP initiative, to identify key disease areas/therapy types meriting concerted investment, and will work with other interested funders to develop mechanisms to capture these opportunities."
Then, like many other areas of leading edge research too, the work has to be interdisciplinary to be successful. In this respect, the report merely states the obvious, namely that people have to communicate with each other and funding organisations try to help them with the networking. The problems arising from the separate cultures found in relevant disciplines, such as clinical medicine and engineering, are only acknowledged in passing, as the report states that, while the community expressed the wish for more interdisciplinary working, "there exist community-based hurdles to its formation, including the challenge of establishing a common language between disciplines and defining shared and valued goals." It doesn't suggest specific solutions that might bridge the gaps between the disciplines concerned.
Finally, while the report is mainly concerned with the R&D in the UK, it also has to acknowledge the importance of international competition and collaboration. Research elsewhere is simultaneously described as a threat and an opportunity. To make the most of the latter, "the sponsors will work with overseas partners through established long-term relationships and new partnerships to capitalise upon emerging opportunities and provide access to complementary expertise that will benefit UK science," the report states.
Oxford's Paul Fairchild comments: "Recent initiatives to foster collaboration between UK scientists and those in countries such as Israel and China with a strong background in regenerative medicine is likely to bring a new perspective to the field and stimulate promising new avenues of research. The availability of new funding streams for joint projects between laboratories is particularly welcome."
Around the world A look around the globe continues to show a very colourful tapestry of different cultural attitudes to stem cell research and thus to the options of regenerative medicine. For instance, researchers in Germany are still banned from producing human embryonic stem cells and can only use imported cell lines if they were produced before 1 st May 2007. In the US, opinions are divided and regulations differ between states, while countries such as Israel and South Korea enthusiastically support stem cell research.
The debate over ethical concerns raised especially by the Christian churches has recently been highlighted, when the Vatican's scientific academy cancelled a conference on adult stem cells that was due to be held at the end of April. The organiser's brief to focus on "responsible stem cell research", i.e. to exclude research on embryonic stem cells, had already divided the research community, with some scientists accepting the invitation, while others called to boycott the event.
On the other side of the debate, the fact that some of the invited speakers, including keynote speaker George Daley from the Children's Hospital at Boston (Massachusetts), are famous for their work with embryonic stem cells, produced disquiet among the members of the Pontifical Academy for Life, which organised the event. While the academy cited organisational reasons for the cancellation, internal debate on the choice of speakers may conceivably have had something to do with it. Which would be ironic, because today, more than ever, regenerative medicine has a range of options beyond the use of embryonic stem cells.
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